![Steven N. Gordon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Steven N. Gordon
Chief Administrative Officer at Kadmon Corp. LLC
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Harlan Waksal | M | 71 |
Kadmon Corp. LLC
![]() Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 11 years |
Steven Meehan | M | 59 |
Kadmon Corp. LLC
![]() Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 7 years |
Anastasios Konidaris | M | 57 |
Kadmon Corp. LLC
![]() Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 7 years |
Philip Barach | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Dixon Boardman | M | - |
Kadmon Corp. LLC
![]() Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 11 years |
Alexandria Forbes | M | 59 |
Kadmon Corp. LLC
![]() Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 14 years |
Thomas Shenk | M | 77 |
Kadmon Corp. LLC
![]() Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 6 years |
Bart M. Schwartz | M | 77 |
Kadmon Corp. LLC
![]() Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 9 years |
Susan Wiviott | F | 66 |
Kadmon Corp. LLC
![]() Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 10 years |
Eugene Bauer | M | 81 |
Kadmon Corp. LLC
![]() Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 14 years |
John Ryan | M | 80 |
Kadmon Corp. LLC
![]() Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | 13 years |
David Cohen | M | 59 | 5 years | |
Cynthia Flowers | F | 64 | 5 years | |
Francois Maisonrouge | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Peter Simon | M | 75 |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
David Freidman | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Steven N. Gordon | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Christina M. Ramirez | M | - |
Équilibre BioPharmaceuticals Corp.
![]() Équilibre BioPharmaceuticals Corp. BiotechnologyHealth Technology Équilibre BioPharmaceuticals Corp. is an innovative biopharmaceutical company based in New York, NY. The company focuses on identifying and developing high-potential drugs for patients who are treatment resistant or unresponsive to other existing medications. The company's approach is to leverage their biopharmaceutical industry expertise to further expand their portfolio of product opportunities. The company is a patient-focused and science-minded company determined to have best and first-in-class therapeutics. The CEO of the company is Philip Barach. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gregory S. Moss | M | 40 | 10 years | |
Arthur Kirsch | M | 72 | 2 years | |
Sheng Da Zan | M | 61 | 3 years | |
Andrew Cohen | M | 52 | 6 years | |
Konstantin Poukalov | M | 40 | 6 years | |
Larry Witte | M | 79 | 6 years | |
Lawrence K. Cohen | M | 70 | 3 years | |
Zhen Ping Zhu | M | 59 | - | |
Charles E. Darder | M | - | - | |
Eva Heyman | F | - | - | |
Kyle Carver | M | - | 8 years | |
Haya Taitel | M | 61 | 3 years | |
Brianne Jahn | M | 38 | 8 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 31 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Steven N. Gordon
- Personal Network